Meticulous Research®—a leading global market research company, published a research report titled, ‘Africa IVD Market by Product & Services, Technology (Immunoassay, Point of Care, Molecular Diagnostics, Coagulation), Application (Infectious Diseases, Diabetes, Oncology), Diagnostic Approach (Lab, OTC, PoC), Customer Type — Forecast to 2029.’
According to this latest publication from Meticulous Research®, the Africa in vitro diagnostics market is expected to reach $1.78 billion by 2029, at a CAGR of 4.8% from 2022 to 2029. The high prevalence of infectious diseases, the rising burden of chronic diseases, the rising initiatives to support the healthcare sector, and the growing awareness regarding the importance of early disease diagnosis drive the growth of the Africa IVD market. However, poor healthcare facilities and infrastructure in African countries are a major challenge to the market's growth.
The Africa IVD market is segmented based on Product Category (Reagents, Assays, and Kits, Instruments, and Software & Services), Technology (Immunoassay, Whole Blood Glucose Monitoring, Point-of-Care Diagnostics, Clinical Chemistry, Molecular Diagnostics, Hematology, Coagulation & Hemostasis, Critical Care, Urinalysis, and Other IVD Technologies), Application (Infectious Diseases, Oncology, Diabetes, Endocrinology, Cardiology, and Other Applications), Diagnostic Approach (Laboratory Testing, Point of Care Testing, and OTC/Self Testing), and Customer Type (Hospital Labs, Private Labs, Home Care/Self Testing, Government, and Other Customer Types), and Geography. The study also evaluates industry competitors and analyzes their market shares.
Based on product category, in 2022, the reagents, assays, and kits segment is expected to account for the largest share of the Africa IVD market. The large market share of this segment is attributed to the frequent utilization of IVD assays & kits in the diagnosis and management of various chronic diseases, the commercial availability of a wide range of reagents & consumables for the diagnosis of various communicable and non-communicable diseases, the increasing awareness about the importance of early diagnosis, and the increase in the volume of testing for infectious diseases such as COVID-19, malaria and influenza.
Based on technology, in 2022, the immunoassay segment is expected to account for the largest share of the Africa IVD market. The large market share of this segment is attributed to the higher preference for immunoassays due to their benefits, such as ease of use, faster turnaround time, higher diagnosis accuracy, and cost-effectiveness.
Based on application, in 2022, the infectious diseases segment is expected to account for the largest share of the Africa IVD market. The large market share of this segment is attributed to the significant burden of emerging and re-emerging infections in Africa and the presence of favorable initiatives to improve diagnostic rates.
Based on diagnostic approach, in 2022, the laboratory testing segment is expected to account for the largest share of the Africa IVD market. The large market share of this segment is attributed to the availability of several IVD tests in laboratories and the higher accuracy of laboratory testing.
Based on customer type, in 2022, the hospital laboratories testing segment is expected to account for the largest share of the Africa IVD market. The large market share of this segment is attributed to the high patient inflow to the hospitals.
This research report analyzes the market across major African countries and provides a comprehensive analysis of South Africa, Algeria, Nigeria, Kenya, Morocco, Tunisia, Tanzania, Egypt, and the rest of Africa.
Download Free Research PDF @ https://www.meticulousresearch.com/download-sample-report/cp_id=5415
Key companies operating in the Africa IVD market are Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), bioMérieux SA (France), Danaher Corporation (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), QIAGEN N.V. (Netherlands), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Illumina, Inc. (U.S.), and Shenzhen Mindray Bio-Medical Electronics Co., Ltd (China).
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
Dental Practice Management Software Market Worth $ 3.11 Billion by 2029Read More